Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Verici Dx Plc ( (GB:VRCI) ) has issued an update.
Verici Dx reported a strong start to 2026, with Tutivia™ test volumes rising 32% quarter-on-quarter to 392 and 34% year-on-year in the first quarter, outpacing management expectations. Seven new transplant centres began ordering tests, a second centre integrated Tutivia into clinical protocols, and overall adoption now spans centres representing about 20% of annual U.S. kidney transplants.
The company’s commercial momentum is supported by broader reimbursement, with Tutivia now covered under Medicare and 17 state Medicaid programmes, improving payment speed and access. Verici Dx also strengthened its sales capability by appointing industry veteran Keith Gilliard as Senior Director of Sales, reinforcing its push for further market penetration ahead of full-year 2025 results due by the end of May 2026.
Spark’s Take on VRCI Stock
According to Spark, TipRanks’ AI Analyst, VRCI is a Neutral.
Verici Dx Plc’s overall stock score is driven by positive corporate events and technical indicators, which are offset by financial performance challenges and valuation concerns. The company’s strategic initiatives and market expansion efforts are promising, but ongoing profitability and cash flow issues present significant risks.
To see Spark’s full report on VRCI stock, click here.
More about Verici Dx Plc
Verici Dx plc, listed on AIM, is a precision diagnostics company focused on improving care for organ transplant patients. It uses multiomic analysis and proprietary artificial intelligence to develop predictive tests that help clinicians optimise therapy, guide biopsy decisions and stratify risk, with its lead product Tutivia™ targeting early detection of acute kidney transplant rejection.
Headquartered in Cardiff in the UK and Franklin, Tennessee in the U.S., Verici Dx operates at the intersection of laboratory and data science. Its tests are designed to rigorous scientific standards and validated in real-world, diverse patient populations to ensure clinical relevance and reliability for transplant centres and healthcare payers.
Average Trading Volume: 1,384,970
Technical Sentiment Signal: Sell
Current Market Cap: £7.19M
Learn more about VRCI stock on TipRanks’ Stock Analysis page.